CO2 Laser Treatment of Xanthelasma Palpebrarum in skin, Aden, Yemen
DOI:
https://doi.org/10.37375/sjms.v1i1.287Keywords:
Xanthelasma Palpebrarum, CO2 laser Treatment, Aden, YemenAbstract
Background: Xanthelasma palpebrarum clinically presents as yellowish plaques on the upper and/or lower eyelids. CO2 laser is considered the gold-standard for its treatment.
Objectives: To evaluate the effectiveness of CO2 laser in the treatment of patients with xanthelasma palpebrarum.
Patients and methods:
Fifty eight patients were presented to our clinics in Almansoora and Khormakser in Aden, during the period January 2020 to December 2020 with xanthelasma palpebrarum and treated with CO2 Laser.
Results:
The study patients were 58 included in the study, the females were (81%) and the males were (19%).
The mean age of all patients was 49.2 ± 9.4 years and their age ranged between 32 – 68 years (p ≤0.05). The age group 50 years old and less represent (53.4%).
We treated the patients with CO2 laser and the results were excellent among (75.9%) patients and good results among (17.2%) patients.
More excellent results were among patients aged ≤ 50 years old, good results were predominant among patients aged more than 50 years old. The difference between values was statistically significant (p = 0.005).
We observed the side effect as follows: hypopigmentation in (10.3%) patients, hyperpigmentation in (3.4%) patients and erythema in (5.2%).
Three patients (5.2%) developed a recurrence of xanthelasma.
In our study cholesterol level was found high in (17.2%) distributed among patients of age group ≤ 50 years old with (5.2%) and among age group > 50 years old with (12.1%) patients.
Conclusion: In our study, excellent results were predominant followed by few numbers of good results. Further studies needed for more patients.
References
Alster T, Hirsch R (2003). Single-pass CO2 laser skin resurfacing of light and dark skin: extended experience with 52 patients. J Cosmet Laser Ther. vol. 5, pp. 39-42.
Alster TS, Garg S (1996). Treatment of facial rhytides with a high-energy pulsed carbon dioxide laser. Plast Reconstr Surg, vol. 98, pp. 791-4.
Alster TS, Lupton JR (2002). Prevention and treatment of side effects and complications of cutaneous laser resurfacing. Plast Reconstr Surg, vol. 109, pp. 308-16.
Bergman R. (1994). The pathogenesis and clinical significance of xanthelasma palpebrarum. J Am Acad Dermatol, vol. 30, pp. 236-42.
Borelli C, and Kaudewitz P (2001). Xanthelasma palpebrarum: treatment with the erbium:YAG laser. Lasers Surg Med, vol. 29, pp. 260-4.
Cruz PD, Jr, East C, Bergstresser PR (1988). Dermal, subcutaneous, and tendon xanthomas: Diagnostic markers for specific lipoprotein disorders. J Am Acad Dermatol, vol. 19, pp. 95–111.
Esmat Samia M, Elramly Amany Z, Abdel Halim Dalia M, Gawdat Heba I, Taha Hanaa I (2014). Fractional CO2 Laser Is an Effective Therapeutic Modality for Xanthelasma Palpebrarum: A Randomized Clinical Trial. Dermatologic Surgery, vol. 40, no. 12, pp. 1349-1355.
Gangopadhyay DN, Dey SK, Chandra M, Pal D, Chaudhary S (1998). Serum lipid profile in xanthelasma. Indian J Dermatol, vol. 43, pp. 53–56
Jain A, Goyal P, Nigam PK, Gurbaksh H, Sharma RC (2007). Xanthelasma palpebrarum-clinical and biochemical profile in a tertiary care hospital Delhi. Indian J Clin Biochem, vol. 22, pp. 151-153.
James W, Berger TG, Elston DM (2011). Andrew's disease of the skin clinical dermatology.10TH ed. Philadelphia: Saundres & Elsevier, pp. 531-32.
Katz TM, Goldberg LH, Friedman PM (2009). Fractional photothermolysis: a new therapeutic modality for xanthelasma. Arch Dermatol, vol. 145, pp. 1091-1094.
Kavoussi H, Ebrahimi A, Rezaei M, Ramezani M, Najafi B, Kavoussi R (2016). Serum lipid profile and clinical characteristics of patients with xanthelasma palpebrarum. An Bras Dermatol, vol. 91, no. 4, pp. 468-471
Laftah Z, Al-Niami (2018). Xanthelasma: An Update on Treatment Modalities. J Cutan Aesthet Surg, vol. 11, no. 1, pp. 1-6.
Nair PA, Patel CR, Ganjiwale JD, Diwan NG, Jivani NB (2016). Xanthelasma palpebrarum with arcus cornea: a clinical and biochemical study. Indian J Dermatol, vol. 61, no, 3, pp. 295–300.
Nouri, K (2012). Lasers in dermatology and medicine. Springer-Verlag London Ltd. https://doi.org/10.1007/978-0-85729-281-0
Ozdoel S, Sahin S, Tokgözoglu L (2008). Xanthelasma palpebrarum and its relation to atherosclerotic risk factors and lipoprotein (a). Int J Dermatol, vol. 47, pp. 785-589.
Pandhi D, Gupta P, Singal A, Tondon A, Sharma S, Madhu SV (2012). Xanthelasma palpebrarum: a marker of premature atherosclerosis (risk of atherosclerosis in xanthelasma). Postgrad Med J, vol. 88, no, 1038, pp. 198-204.
Park EJ, Youn SH, Cho EB, Lee GS, Hann SK, Kim, KH (2011). Xanthelasma palpebrarum treatment with a 1,450-nm-diode laser. Dermatol Surg, vol. 37, pp. 791-796.
Pathania V, Chatterjee M (2015). Ultrapulse carbon dioxide laser ablation of xanthelasma palpebrarum: a case series. J Cutan Aesthet Surg, vol. 8, no 1, pp. 46–49
Pragya A Nair, Rochit Singhal (2018). Xanthelasma Palpebrarum–A brief review. Clin Cosmet Investig Dermatol, vol. 11, pp. 1–5.
Raulin C, Schoenermark MP, Werner S, Greve B (1999). Xanthelasma palpebrarum: treatment with the ultrapulsed CO2 laser. Lasers Surg Med, vol. 24, no 2, pp. 122–127.
Rohrich RJ, Janis JE, Pownell PH (2002). Xanthelasma palpebrarum: a review and current management principles. Plast Reconstr Surg, vol. 110, no 5, pp. 1310–1318
Rubinstein TJ, Mehta MP, Schoenfield L, Perry JD (2014). Orbital xanthogranuloma in an adult patient with xanthelasma palpebrarum and hypercholesterolemia.Ophthal Plast Reconstr Surg, vol. 30, pp. 6-8.
Sarkany RPE, Breathnach SM, Seymour CA, Weismann K, Burns DA (2010). Metabolic and Nutritional Disorders. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's textbook of dermatology. vol. 3. 8th ed. Oxford: Wiley-Blackwell, 57, pp. 60-75.
Schoenermark MP, and Raulin C. (1996). Treatment of xanthelasma palpebrarum with the pulsed dye laser. Lasers Surg Med, vol. 19, pp. 336-339.
Segal P, Insull W Jr, Chambless LE, et al. (1986). The association of dyslipoproteinemia with corneal arcus and xanthelasma. The lipid research clinics program prevalence study. Circulation, vol. 73, no 1 Pt 2, pp. I108–I118.
Sharma P, Patgiri D, Sharma G, Pathak MS (2013). Serum lipid profile in Xanthelasma palpebrum. Indian J Basic Appl Med Res, vol. 7, pp. 732-737.
Zak A, Zeman M, Slaby A, Vecka M. (2014). Xanthomas: Clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, vol. 158, pp. 181–188.
